Ozempic, Wegovy among drugs selected for Medicare's price negotiations
The Biden administration announced Friday that Ozempic, Wegovy and 13 additional drugs will now be covered under Medicare Part-D for price negotiations, the next round of negotiations under the Inflation Reduction Act passed by President Joe Biden in 2022.
Medicare will seek to negotiate lower list prices for the blockbuster diabetes and weight loss drugs Ozempic and Wegovy and 14 other medications, a cost-saving move that would take effect in 2027.
President Biden took a groundbreaking step in proposing to cover GLP-1 obesity medications under Medicare and Medicaid in November. But on Friday, his administration announced that Wegovy ...
Just how much Medicare price negotiations will negatively impact Novo Nordisk, though, depends on what the final negotiated ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback